# Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension

> **NCT00765947** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 256 (actual)

## Conditions studied

- Essential Hypertension ( Mild to Moderate)

## Interventions

- **DRUG:** Aliskiren
- **DRUG:** Hydrochlorothiazide
- **DRUG:** Amlodipine

## Key facts

- **NCT ID:** NCT00765947
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2020-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00765947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00765947, "Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00765947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*